The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted
to affect specific genes that are mutated as part of the disease. Mutations in genes can lead
to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of
the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled
to one of the treatment arms. These arms have treatments specifically directed to the mutated
genes. Patients that do not have a greater than 25% mutation to the genes listed can be
enrolled to a non-actionable treatment arm.
The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002
study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related
Plasma Cell Malignancies. (NCT02884102).
The study will enroll 228 patients enrolled to one of eight treatment arms. The study is open
to patients relapsing with relapsed refractory multiple myeloma, who have
received at least one prior but no more than 3 prior therapies
exposed to both a PI and an IMiD
had early relapse after initial treatment. Relapse is defined as the IMWG uniform
response criteria (Kumar et al, 2016). Early relapse as defined by at least one of the
Relapse within 3 years post autologous stem cell transplantation (ASCT) on
maintenance, or 18 months if unmaintained
Relapse within 18 months of initial non-ASCT based therapy
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.